Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type met...
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study
About this item
Full title
Author / Creator
Xu, Xiaojing , Ai, Luoyan , Hu, Keshu , Liang, Li , Lv, Minzhi , Wang, Yan , Cui, Yuehong , Li, Wei , Li, Qian , Yu, Shan , Feng, Yi , Liu, Qing , Yang, Ying , Zhang, Jiao , Xu, Fei , Yu, Yiyi and Liu, Tianshu
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Immunotherapy confers little to no benefit in the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Mechanistic insights suggested that epidermal growth factor receptor (EGFR) antibody plus irinotecan might augment the tumor immune response in mCRC. Therefore, we conducted a proof-of-concept, single-arm, phase 2 study (C...
Alternative Titles
Full title
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_c52ef4cf4de347268916103efecfb9a4
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c52ef4cf4de347268916103efecfb9a4
Other Identifiers
ISSN
2041-1723
E-ISSN
2041-1723
DOI
10.1038/s41467-024-51536-x
